Supermicro Completes Independent Investigation into March 2026 Export-Control Matter
No evidence of senior management knowledge or company-level wrongdoing found.
Already have an account? Sign in.
No evidence of senior management knowledge or company-level wrongdoing found.
Beauty giant Coty forecasts current-quarter EPS below expectations and declines to give annual guidance, citing a complex transition year.
AX-0810 Phase 1 shows dose-dependent bile acid increases and no serious adverse events, delivering the first human proof of concept for ProQR’s Axiomer RNA editing.
Cantor Fitzgerald initiates Overweight coverage on Milestone, citing Cardamyst’s strong PSVT launch potential and $250-300M peak sales outlook.